Hyperliquid ups equity facility to $2.5B; share cap nears

Hyperliquid Strategies amended its committed equity facility with Chardan Capital Markets to $2.5 billion. The company’s annual report discloses at least $763.7 million of proceeds raised under the facility, leaving roughly $236.3 million before aggregate facility sales reach $1 billion, at which point a price-specific Nasdaq limitation applies.

Filings show $646.6 million of gross proceeds from facility sales through June 30, plus $117.1 million of additional facility sales after the quarter end. The June 30 proceeds had an average issue price of $8.70. The amended agreement increased the formal commitment from $1.0 billion to $2.5 billion, but the practical availability of the expanded amount depends on sale prices and other conditions disclosed in the filings.

Under the amendment, once aggregate facility sales exceed $1 billion, the company cannot complete a sale if doing so would push the total number of facility shares issued at prices below $12.02 above 42,641,847 shares. That share count equals 19.99% of Hyperliquid’s pre-amendment outstanding common stock or voting power. Shares sold at $12.02 or higher do not count toward that price-specific cap.

The filings provide aggregate proceeds, total facility shares and an average issue price, but they do not include transaction-level pricing. Without that breakdown, the remaining count of shares issued below $12.02 that would fit under the 42,641,847-share limit cannot be calculated from the disclosed information.

Hyperliquid has used proceeds from the facility to buy HYPE tokens. An August 27 update stated the company had deployed $773.4 million to acquire about 16.5 million HYPE and held roughly 29.3 million HYPE in total at that time. The $646.6 million reported through June 30 does not include the $117.1 million in post-quarter facility sales disclosed in the annual report.

The equity facility is a committed line of financing, not an obligation to issue shares. Access to the full $2.5 billion commitment will depend on future sale prices, how Nasdaq treats other transactions as part of the same issuance, remaining capacity under the 19.99% exchange cap and whether shareholders must authorize additional discounted share issuances. The company’s September 1 filing did not update the facility utilization total, leaving the exact remaining capacity before the price-specific restriction takes effect unclear.

If additional facility sales increase the count of shares sold below $12.02 beyond the capped amount, shareholder approval would generally be required unless Nasdaq rules provide an exemption. The amendment also allows the cap to be reduced by other transactions that Nasdaq treats as part of the same issuance, which could affect long-term issuance capacity through the facility.